Alternatives Spleißen als therapeutisches Target für Erkrankungen des Herzens


Förderkennzeichen

81Z2100102

Projektnummer

450

Institution
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter
Michael Gotthardt
Standort
Berlin
Kurzbeschreibung

The project „alternative splicing as a therapeutic target for cardiac diseases“ builds on our identification of RBM20 as a splice factor with substrates related to sarcomere function and … 

The project „alternative splicing as a therapeutic target for cardiac diseases“ builds on our identification of RBM20 as a splice factor with substrates related to sarcomere function and calcium homeostasis. We will study the regulation of RBM20 expression and function, as well as its interaction with other proteins to identify potential therapeutic targets. Through the coordinated interference with cardiac isoform expression, we will adapt the elastic and electrical properties of the heart.

Projektart
Standortprojekt
Stichwörter
RNA, splicing, therapy
Topic
cardiomyocyte function
Fördersumme
€ 357.275,80
Beginn
01.01.2015
Ende
31.12.2018